← Back to dossier
Patient handout

Distal DVT (isolated calf vein)

PRODUCTION

1. Your condition

This handout is for distal dvt (isolated calf vein). Your care team identified this based on: isolated calf pain, swelling, tenderness without thigh involvement → suggests distal dvt.

Other reasons your team may use this plan: compression us shows non-compressible distal vein (peroneal, posterior tibial, soleal) with patent popliteal/femoral → isolated distal dvt (iddvt); whole-leg compression us identifies isolated distal dvt not detected by proximal-only protocol (bernardi 2008).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
apixaban10 mg BID × 7 d → 5 mg BIDPOBID × 6-12 weeksAMPLIFY (PMID 23808982) for full-dose efficacy; ACCP 2021 supports DOAC for IDDVT requiring AC
rivaroxaban15 mg BID × 21 d → 20 mg dailyPOBID then daily × 6-12 weeksEINSTEIN-DVT PMID 21128814 — non-inferior to standard care
enoxaparin1 mg/kg SC BIDSCBIDLMWH preferred in pregnancy and select cancer-VTE per CARAVAGGIO PMID 32223112

Plan: Isolated distal DVT — AC vs surveillance decision (ACCP 2021)

3. When to call your provider

Contact your care team if any of the following happen:

  • Recurrent VTE → re-evaluate per parent dossier
  • New cancer dx → cancer-VTE evaluation

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • Extension of distal DVT to popliteal vein on serial US (during surveillance pathway or despite AC)
  • Major bleed on AC for IDDVT (Hgb drop ≥2, transfusion, ICH, retroperitoneal) — particularly concerning given lower benefit threshold for IDDVT(life-threatening)
  • Patient on surveillance pathway returns with worsening symptoms or extension on repeat US

5. Follow-up

AC pathway: stop at 6-12 weeks if provoked + transient risk; consider extended only if extension or unprovoked + high recurrence risk. Surveillance pathway: convert to proximal pathway if extension

6. Sources

Guideline: ACCP/CHEST 2021 Antithrombotic + ASH 2020 VTE Treatment

  1. pubmed.ncbi.nlm.nih.gov/34352278
  2. pubmed.ncbi.nlm.nih.gov/33007077
  3. pubmed.ncbi.nlm.nih.gov/27836513